Your browser is no longer supported. Please, upgrade your browser.
Settings
PCYC [NASD]
Pharmacyclics Inc.
Index- P/E198.10 EPS (ttm)1.09 Insider Own0.50% Shs Outstand76.02M Perf Week21.61%
Market Cap16.41B Forward P/E55.10 EPS next Y3.92 Insider Trans-12.54% Shs Float61.27M Perf Month30.54%
Income86.90M PEG1238.13 EPS next Q0.10 Inst Own77.20% Short Float8.47% Perf Quarter55.74%
Sales563.10M P/S29.15 EPS this Y-45.30% Inst Trans1.28% Short Ratio4.81 Perf Half Y75.47%
Book/sh9.57 P/B22.56 EPS next Y423.93% ROA10.50% Target Price183.47 Perf Year49.34%
Cash/sh9.69 P/C22.29 EPS next 5Y0.16% ROE13.00% 52W Range82.51 - 231.09 Perf YTD76.62%
Dividend- P/FCF133.67 EPS past 5Y24.50% ROI10.70% 52W High-6.56% Beta0.60
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin94.60% 52W Low161.70% ATR9.82
Employees484 Current Ratio6.00 Sales Q/Q161.80% Oper. Margin45.30% RSI (14)84.59 Volatility9.05% 5.39%
OptionableYes Debt/Eq0.00 EPS Q/Q-3.60% Profit Margin15.40% Rel Volume1.88 Prev Close217.82
ShortableYes LT Debt/Eq0.00 EarningsFeb 18 AMC Payout0.00% Avg Volume1.08M Price215.93
Recom2.00 SMA2024.31% SMA5043.01% SMA20075.09% Volume2,024,322 Change-0.87%
Feb-26-15Downgrade WallachBeth Buy → Hold $228
Feb-19-15Reiterated Deutsche Bank Buy $180 → $205
Feb-19-15Downgrade ROTH Capital Buy → Neutral $189 → $187
Jan-29-15Reiterated ROTH Capital Buy $188 → $189
Oct-17-14Reiterated ROTH Capital Buy $185 → $188
Oct-14-14Reiterated ROTH Capital Buy $183 → $185
Aug-01-14Upgrade WallachBeth Hold → Buy
May-27-14Downgrade RBC Capital Mkts Outperform → Sector Perform $110 → $95
May-05-14Reiterated RBC Capital Mkts Outperform $150 → $110
Feb-21-14Reiterated Deutsche Bank Buy $170 → $180
Dec-18-13Initiated WallachBeth Hold $108
Sep-26-13Initiated Deutsche Bank Buy $170
Dec-12-12Reiterated Wedbush Outperform $93 → $110
Aug-24-12Initiated Stifel Nicolaus Hold
Aug-02-12Downgrade Needham Buy → Hold
May-17-12Reiterated Rodman & Renshaw Mkt Outperform $22 → $40
May-17-12Reiterated Needham Buy $23 → $32
Feb-21-12Upgrade RBC Capital Mkts Sector Perform → Outperform $15 → $34
Dec-09-11Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $15
Dec-09-11Downgrade Global Hunter Securities Buy → Neutral $15 → $15
Feb-27-15 02:45PM  Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases PR Newswire
02:30PM  In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody PR Newswire
11:31AM  Cramer: Pharmacyclics-Johnson & Johnson Deal Unlikely at This Price at TheStreet
09:52AM  Cramer's Stop Trading: PCYC CNBC
09:30AM  The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Zacks
Feb-26-15 11:10AM  Biotech Making A Comeback - Here Is One Stock to Watch Company Spotlight
11:07AM  Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Zacks
10:08AM  Credit Suisse Downgrades Pharmacyclics Amid Takeover Rumors Benzinga
09:30AM  Familiar ETF Friend Will Enjoy a Pharmacyclics Sale ETF Trends
09:00AM  Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Zacks
06:54AM  Pharmacyclics downgraded by WallachBeth Briefing.com
Feb-25-15 09:07PM  Cancer Drug Once Bought for $7 Million May Now Fetch $18 Billion Bloomberg +16.86%
06:51PM  Pharmacyclics said to weigh sale of U.S. cancer drugmaker at San Jose Mercury News
05:16PM  Pharmacyclics considers $19bn sale at Financial Times
04:24PM  Pharmacyclics Weighs Sale of $15 Billion U.S. Drugmaker Bloomberg
02:32PM  Pharmacyclics mulls sale; J&J, Novartis interested - Bloomberg Reuters
02:31PM  Biotech Pharmacyclics Spikes On Buyout Rumors at Investor's Business Daily
01:19PM  Pharmacyclics mulls selling itself; J&J, Novartis interested-Bloomberg Reuters
01:04PM  PHARMACYCLICS INC Financials EDGAR Online Financials
12:46PM  Pharmacyclics Said to Weigh Sale of $15 Billion U.S. Drugmaker at Bloomberg
09:17AM  Can the Rally in Pharmacyclics (PCYC) Shares Continue? - Tale of the Tape Zacks
Feb-23-15 06:22PM  Medical Stocks Lead New Highs On Merger News at Investor's Business Daily +5.77%
Feb-20-15 07:07PM  10-K for Pharmacyclics, Inc. Company Spotlight
04:56PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Feb-19-15 02:38PM  Street talk: DAL, NCLH, TSCO, TSLA & PCYC CNBC
02:25PM  Analysts Respond To Pharmacyclics' Q4 Results Benzinga
09:50AM  Pharmacyclics Misses on Q4 Earnings, Reiterates 2015 View - Analyst Blog Zacks
09:42AM  Nomura Upgrades Pharmacyclics, Sees 'Upside' To Stock Benzinga
Feb-18-15 04:18PM  Pharmacyclics misses 4Q profit forecasts AP
04:15PM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
04:01PM  Pharmacyclics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Updates PR Newswire
07:07AM  Q4 2014 Pharmacyclics Inc Earnings Release - After Market Close CCBN
Feb-17-15 12:48PM  Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks - Earnings ESP Zacks
10:28AM  J&J-Pharmacyclics drug shows potential in high-risk leukemia patients Reuters
09:00AM  IMBRUVICA® (ibrutinib) Treatment Shows Efficacy and Tolerability in Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant PR Newswire
08:51AM  Why Earnings Season Could Be Great for Pharmacyclics (PCYC) - Tale of the Tape Zacks
Feb-14-15 08:02AM  Actavis Leads IBD 50 Stocks With Earnings This Week at Investor's Business Daily
Feb-12-15 10:40AM  Pharmacyclics Announces Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results PR Newswire
Feb-11-15 07:54AM  JMP Securities Covers Mostly Good News From Pharma Pending More Visibility Benzinga
Feb-03-15 12:20PM  Can Edwards Lifesciences (EW) Surprise Earnings in Q4? - Analyst Blog Zacks
Feb-02-15 04:32PM  Monday's Market Recap Yahoo Finance Contributors
04:31PM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Jan-30-15 05:55PM  Pharmacyclics Up on Imbruvica Label Expansion in the U.S. - Analyst Blog Zacks
12:38PM  3 Biotechs Looking Good this Earnings Season - Earnings ESP Zacks
Jan-29-15 11:43AM  U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom's macroglobulinemia (WM) PR Newswire
11:29AM  FDA expands use of Imbruvica to treat rare form of cancer Reuters
Jan-23-15 06:34PM  IBD 50 Turns In Solid Week As Market Uptrend Resumes at Investor's Business Daily
04:35PM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:40AM  Why You Shouldn't Bet Against Pharmacyclics (PCYC) Stock - Tale of the Tape Zacks
Jan-20-15 08:43AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
08:36AM  Why Pharmacyclics (PCYC) Could Be Positioned for a Surge? - Tale of the Tape Zacks
Jan-16-15 08:44AM  Can The Uptrend Continue for Pharmacyclics (PCYC)? - Tale of the Tape Zacks
08:02AM  These Top 10 Health Care Funds Are Full Of Vitality at Investor's Business Daily
Jan-15-15 09:30AM  The Zacks Analyst Blog Highlights: NPS Pharmaceuticals, Celgene, Pharmacyclics, Agenus and Incyte - Press Releases Zacks
07:00AM  Pharmacyclics Inc. (PCYC): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Jan-14-15 06:08PM  Nasdaq stocks posting largest percentage increases AP
02:39PM  Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst Blog Zacks
Jan-13-15 01:13PM  Midday movers: Aetna, Ocwen Financial, GoPro & more at CNBC +16.40%
11:29AM  Pharmacyclics Soars As Imbruvica Sales Beat Estimates at Investor's Business Daily
09:29AM  Tuesday Morning Movers: ChannelAdvisor Plummets Benzinga
09:18AM  Ahead of the Bell: Pharmacyclics shares soar AP
06:01AM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
Jan-12-15 06:55PM  Alcoa shares rise on earnings, sales beat at MarketWatch
05:45PM  Pharmacyclics Announces Preliminary 2014 U.S. Net Product Revenue Results and 2015 U.S. Net Product Revenue Outlook PR Newswire
Jan-07-15 02:51PM  Wells Fargo Top Biotech Stocks for 2015 at 24/7 Wall St.
09:15AM  Analysts 5 Top Momentum Stocks for 2015 With Huge Upside Potential at 24/7 Wall St.
Jan-06-15 10:23AM  Gilead Sciences: Looking Beyond Hepatitis C at Barrons.com
07:38AM  UPDATE: BTIG Initiates Coverage On Pharmacyclics Benzinga
Jan-05-15 09:00AM  IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients PR Newswire
Jan-02-15 04:27PM  At Pharmacyclics, Employees Train To Become Geniuses at Investor's Business Daily
Dec-22-14 09:00AM  Pharmacyclics Announces Update on IMBRUVICA® (ibrutinib) Waldenstrom's macroglobulinemia (WM) Submission PR Newswire
Dec-12-14 09:00AM  Pharmacyclics Named 2014 Outstanding Company by BayBio PR Newswire
Dec-11-14 06:01AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Dec-09-14 04:10PM  Pharmacyclics Presents Imbruvica Data at the ASH Meeting Zacks
02:02PM  UPDATE - IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy PR Newswire
Dec-08-14 09:30PM  IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma PR Newswire
09:01PM  Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL) PR Newswire
08:45PM  IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy PR Newswire
05:50PM  Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry Zacks
01:41PM  Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) GlobeNewswire
Dec-06-14 03:01PM  IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma PR Newswire
Dec-05-14 09:00AM  Pharmacyclics Announces Launch of informCLL Registry for Chronic Lymphocytic Leukemia (CLL) Patients PR Newswire
06:45AM  Biotech stocks to watch at ASH CNBC
Dec-04-14 09:00AM  Pharmacyclics Receives 2014 Society for Medicines Research Award for Drug Discovery for Ibrutinib (IMBRUVICA®) PR Newswire
02:24AM  Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? (Revised) Zacks
Dec-03-14 05:57AM  Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? Zacks
Dec-02-14 05:05PM  Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU Zacks
06:01AM  PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Dec-01-14 09:00AM  New IMBRUVICA® (ibrutinib) Application Accepted by European Medicines Agency for Waldenstrom's Macroglobulinemia PR Newswire
Nov-28-14 06:10AM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Nov-12-14 04:07PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Nov-09-14 07:09PM  10-Q for Pharmacyclics, Inc. Company Spotlight
Nov-07-14 04:52PM  PHARMACYCLICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-06-14 09:29AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
09:09AM  IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting PR Newswire
08:30AM  Keith Lui Joins Versartis to Lead Global Marketing Efforts GlobeNewswire
Nov-05-14 11:00AM  Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca Zacks
Nov-04-14 04:30PM  Pharmacyclics tops Street 3Q forecasts AP
04:13PM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
04:05PM  Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update PR Newswire
Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. The company offers IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under multiple Phase I, II, III clinical trials for the treatment of naive and relapsed/refractory chronic lymphocytic leukemia, naive and relapsed/refractory diffuse large B-cell lymphoma, naive follicular lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory follicular lymphoma, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, and relapsed/refractory marginal zone lymphoma. The company is also developing a BTK inhibitor lead optimization program, which is in Phase I clinical trials targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in multiple Phase I, II clinical trials for the treatment of cancer; and PCI-24781, a HDAC inhibitor abexinostat, which is in multiple Phase I, II clinical trials for the treatment of relapsed/refractory lymphomas and solid tumors. The company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soni Manmeet SinghChief Financial OfficerNov 13Option Exercise61.601,00061,60039,611Nov 17 04:19 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Option Exercise6.843,00020,5206,193Nov 17 04:30 PM
Soni Manmeet SinghChief Financial OfficerNov 13Sale141.441,000141,44238,611Nov 17 04:19 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Sale141.303,000423,9023,193Nov 17 04:30 PM
Zanganeh MakyChief Operating OfficerNov 12Option Exercise7.195,93142,644216,243Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 12Sale137.965,931818,216210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Option Exercise32.381,50048,5701,705Nov 10 06:30 PM
Zanganeh MakyChief Operating OfficerNov 10Option Exercise2.3023,00052,900233,312Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 10Sale133.8323,0003,078,027210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Sale133.871,500200,805205Nov 10 06:30 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Option Exercise6.845,00034,2008,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerNov 07Option Exercise2.301,5513,567211,863Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 07Sale135.011,551209,401210,312Nov 12 06:07 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Sale134.505,000672,5003,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerSep 04Option Exercise2.305,00011,500215,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 04Sale122.005,000610,000210,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Option Exercise2.307,00016,100217,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Sale121.577,000850,980210,311Sep 04 05:54 PM
Love Richard BGeneral CounselAug 27Option Exercise32.381,50048,5701,704Aug 28 09:52 PM
Love Richard BGeneral CounselAug 27Sale124.001,500186,000204Aug 28 09:52 PM
Tan HeowChief Quality&Tech OperationsAug 21Option Exercise27.052,19659,4024,069Aug 22 02:45 PM
Tan HeowChief Quality&Tech OperationsAug 13Option Exercise27.0510,000270,50011,873Aug 13 05:27 PM
Tan HeowChief Quality&Tech OperationsAug 13Sale123.5810,0001,235,8081,873Aug 13 05:27 PM
McGreivy JesseChief Medical OfficerAug 07Option Exercise73.0934,0622,489,51534,062Aug 07 06:51 PM
McGreivy JesseChief Medical OfficerAug 07Sale120.9234,0624,118,6100Aug 07 06:51 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMay 08Option Exercise25.947,710199,9979,653May 08 06:41 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingApr 29Option Exercise57.162,332133,2972,728May 01 06:14 PM
Fardis MariaChief of Oncology Ops & AllianMar 05Option Exercise6.843,00020,5205,988Mar 07 06:06 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Option Exercise0.8615,00012,90053,004Mar 06 06:06 PM
McGreivy JesseChief Medical OfficerMar 05Option Exercise25.336,563166,2416,563Mar 06 04:35 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Option Exercise25.946,253162,2037,992Mar 06 04:33 PM
McGreivy JesseChief Medical OfficerMar 05Sale139.666,563916,5990Mar 06 04:35 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Sale140.756,253880,1151,739Mar 06 04:33 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Sale140.0015,0002,100,03338,004Mar 06 06:06 PM
Fardis MariaChief of Oncology Ops & AllianMar 05Sale140.503,000421,5042,988Mar 07 06:06 PM
Chang Betty YVP, Research/BiologyMar 04Option Exercise10.2417,500179,23821,254Mar 05 08:15 PM
HALVORSON ERIC HDirectorMar 04Option Exercise17.663,47261,3324,472Mar 06 02:46 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Option Exercise25.9413,747356,59715,486Mar 06 04:33 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Sale137.0713,7471,884,3301,739Mar 06 04:33 PM
HALVORSON ERIC HDirectorMar 04Sale138.333,472480,2821,000Mar 06 02:46 PM
Chang Betty YVP, Research/BiologyMar 04Sale137.9717,5002,414,4843,754Mar 05 08:15 PM